Alumni Ventures Group
Alumni Ventures Group is a venture capital firm based in Manchester, New Hampshire, with offices across North America. It provides access to venture investing for individual accredited investors, particularly alumni networks, by offering diversified portfolios of venture opportunities and allowing members to invest alongside fellow alumni in ventures led by peers. The firm backs early-stage and later-stage opportunities across technology, consumer, healthcare, financial services, and other sectors, with a sector- and geography-agnostic approach. It typically invests between $10,000 and $3 million per deal and emphasizes the involvement of alumni connections and an institutional lead investor in opportunities. Alumni Ventures also offers focused funds to broaden participation, enabling accredited investors to access venture portfolios diversified by type, sector, stage, and geography. The model aims to democratize access to venture capital while maintaining rigorous selection standards through alumni networks.
Top Stages
https://crunchbase.com/organization/***
https://linkedin.com/company/***
https://signal.nfx.com/firms/***
Past deals in Medical Devices
Epicore Biosystems
Series B in 2025
Epicore Biosystems, Inc. is a Cambridge, Massachusetts-based company that develops and commercializes a proprietary wearable microfluidic sensing platform designed for athletes. Founded in 2017, the company focuses on analyzing small droplets of sweat directly from the skin to measure a range of health and performance metrics. Its technology allows for non-invasive monitoring of sweat biomarkers, skin health, and physiological states in real-time, facilitating personalized management of hydration, nutrition, and overall health. Epicore's innovative platform is grounded in extensive research in microfluidics and soft materials, aiming to enhance athletic performance and health management through accessible and cost-effective solutions.
Precision Neuroscience
Series C in 2024
Precision Neuroscience is a New York-based neurotechnology company developing a next-generation brain–computer interface platform to enable breakthrough treatments for neurological illnesses affecting billions worldwide. The company aims to deliver minimally invasive, safely removable implants capable of processing large amounts of neural data across multiple brain regions to support therapeutic interventions. Founded in 2021, it focuses on translating neural signals into clinical outcomes, with technology described as a thin-film microelectrode array that conforms to the brain surface without penetrating tissue, enabling broad neural data collection to aid treatment of spinal cord injuries, stroke, and neurodegenerative diseases.
Andromeda Surgical
Seed Round in 2024
Andromeda Surgical develops autonomous robotic systems aimed at enhancing surgical precision, consistency, and efficiency.
CytoVale
Series D in 2024
CytoVale is a medical technology company based in San Francisco that develops biomarkers derived from the mechanical properties of single cells. The company uses microfluidics to route and probe cells, enabling the measurement of multiple biophysical indicators at once. Its technology aims to advance early detection of immune-mediated diseases and sepsis through the analysis of cell mechanics and machine learning. By translating biophysical signals into diagnostic information, CytoVale seeks to improve diagnostic accuracy, support timely treatment decisions, and reduce healthcare costs.
Centaur Labs
Series B in 2024
Centaur Labs provides a platform for expert data annotation services, specializing in medical, scientific, and other complex datasets. It leverages a global network of tens of thousands of students and professionals to deliver accurate and scalable solutions.
Magnetic Insight
Series B in 2024
Magnetic Insight, Inc. is a company specializing in magnetic particle imaging (MPI), an innovative imaging modality that detects iron oxide nanoparticle tracers through time-varying magnetic fields. Founded in 2012 and headquartered in Alameda, California, the company offers several key products, including the MOMENTUM imager, a pre-clinical MPI solution designed to produce high-quality images using advanced magnetic field gradients and proprietary reconstruction processes. Additionally, Magnetic Insight develops VivoTrax, a nanoparticle for cell tracking and as a blood pool agent, and Hyper, an add-on module for the MOMENTUM system that facilitates targeted magnetic hyperthermia treatment. The company's technology enables real-time monitoring of biological events, making significant strides in areas such as quantitative cell tracking, imaging of vascular function, and research into regenerative medicine and CAR-T cell therapies.
Nanochon
Seed Round in 2024
Nanochon is developing an implantable, 3D-printed cartilage implant designed to replace damaged cartilage and promote new tissue growth in joints, with a focus on knee damage. The device combines 3D printing and a novel nanomaterial to enable on-demand, cost-effective solutions intended to restore joint function and improve outcomes for young and active patients.
Epicore Biosystems
Venture Round in 2024
Epicore Biosystems, Inc. is a Cambridge, Massachusetts-based company that develops and commercializes a proprietary wearable microfluidic sensing platform designed for athletes. Founded in 2017, the company focuses on analyzing small droplets of sweat directly from the skin to measure a range of health and performance metrics. Its technology allows for non-invasive monitoring of sweat biomarkers, skin health, and physiological states in real-time, facilitating personalized management of hydration, nutrition, and overall health. Epicore's innovative platform is grounded in extensive research in microfluidics and soft materials, aiming to enhance athletic performance and health management through accessible and cost-effective solutions.
Earli
Series A in 2024
Earli is a biotechnology company focused on advancing cancer detection and treatment through innovative technology. The company specializes in developing devices that utilize a novel gene therapy approach known as Synthetic Biopsy. This method compels cancer cells to produce synthetic biomarkers, which are not naturally occurring in the human body. These biomarkers can then be detected in bodily fluids such as blood, urine, or breath, allowing for early identification of cancer. By facilitating the early detection of homogeneous tumors, Earli aims to significantly improve the chances of successful treatment and personalize therapy options for patients. Additionally, the technology is designed to be visible during imaging procedures such as PET scans, enhancing the monitoring of cancer progression and treatment efficacy.
CytoVale
Series C in 2023
CytoVale is a medical technology company based in San Francisco that develops biomarkers derived from the mechanical properties of single cells. The company uses microfluidics to route and probe cells, enabling the measurement of multiple biophysical indicators at once. Its technology aims to advance early detection of immune-mediated diseases and sepsis through the analysis of cell mechanics and machine learning. By translating biophysical signals into diagnostic information, CytoVale seeks to improve diagnostic accuracy, support timely treatment decisions, and reduce healthcare costs.
Emm
Seed Round in 2023
Emm is a company focused on consumer health technology, developing tools to help individuals manage their health on their terms. It is building a menstrual cup with integrated biosensors designed to track biometric data and deliver personalized insights about menstrual health. The device aims to redefine period experiences by providing actionable information that helps users understand their health through technology and expert knowledge.
Basil Systems
Seed Round in 2023
Basil Systems offers a SaaS analytics platform that uses machine learning to analyze product, market, and regulatory data for medical device and pharmaceutical companies. The platform provides AI-powered insights to inform product development, market strategy, and clinical decisions, helping clients access essential analytics that guide strategic choices, improve product and supply chain quality, mitigate recall risk, and shorten regulatory approval timelines, enabling the delivery of safe products.
TFC Therapeutics
Pre Seed Round in 2023
TFC Therapeutics is a biotechnology company focused on creating innovative biologics aimed at addressing critical factors in cancer recurrence and metastasis. The company develops technology that employs monoclonal antibodies designed to specifically bind to receptors on tumor-initiating cells, known as TMH cells. This targeted approach activates the immune system to effectively destroy these cells, offering new treatment possibilities for cancer within the healthcare sector. Through its research and development efforts, TFC Therapeutics seeks to contribute significantly to advancements in cancer therapy.
VenoStent
Series A in 2023
VenoStent develops bioabsorbable smart polymer wraps for vascular surgeries. Its flagship product, SelfWrap, is a perivascular wrap designed to reduce failures at the vein-artery junction in dialysis patients by promoting outward vein growth and providing custom-fit mechanical support. The company's technology acts as an external stent, reducing surgery time, infection risk, and wound reopening while improving vein usability and durability.
Ossium Health
Series C in 2023
Ossium Health, Inc. is a biotechnology company that specializes in developing and manufacturing advanced cell therapy products aimed at treating blood cancers, improving organ transplantation, and repairing tissue damage caused by radiation exposure. Established in 2016 and based in San Francisco, the company has created a range of therapies, including HPC, Marrow, which consists of human leukocyte antigen (HLA)-matched bone marrow stem cells for hematopoietic reconstitution in blood cancer patients. Additionally, Ossium offers Chimera, designed to enhance organ transplantation, and Chymalis, which utilizes mesenchymal stem cells from bone marrow to facilitate the healing of damaged bone and muscle tissue. The company also supplies bone marrow cells for research in oncology, immunology, and related fields, focusing on improving health and longevity through innovative bioengineering techniques.
Upside Health
Seed Round in 2023
Upside Health, Inc. is a healthcare technology company based in New York, founded in 2017, that focuses on chronic pain management through its innovative mobile application, Ouchie. This application provides patients with targeted educational content and rewards for achieving functional milestones, fostering a supportive community for individuals managing chronic pain. Upside Health's platform includes remote patient monitoring and engagement tools that enable clinicians to access valuable data, improving care outcomes while minimizing additional burdens on healthcare providers. By empowering both patients and clinicians, Upside Health aims to transform the assessment and treatment of chronic pain, ultimately enhancing the quality of care and reducing healthcare costs.
MedScout
Seed Round in 2023
MedScout is a revenue acceleration platform tailored for medical device and diagnostic companies. It offers a sales enablement software that integrates medical claims intelligence from both public and private payors, providing a user-friendly interface specifically designed for sales professionals and leaders. The platform delivers immediate insights into the addressable market within existing territories and facilitates understanding of market dynamics. By supplying comprehensive information on patient demographics, procedure volumes, referral patterns, and payment data, MedScout empowers its clients to optimize their sales strategies and enhance operational productivity, ultimately driving growth in the life sciences sector.
Ascent Integrated Tech
Seed Round in 2023
Ascent develops life-saving technology for first responders, integrating smartwatch data into its Tactical Assault Kit (TAK) platform to enhance firefighter safety, accountability, and operational decision-making. Deployed across major U.S. metro departments and expanding internationally through partnerships.
Mend
Series A in 2023
MEND is a life sciences company dedicated to improving health outcomes through targeted clinical nutrition and medical food interventions. The company focuses on researching and developing products that aid in healing from injuries, surgeries, and illness, as well as enhancing physical performance and addressing the challenges of aging. MEND's innovations have gained acceptance in various sectors, including hospitals, health systems, professional sports teams across major leagues, and elite military forces in the United States. The company's commitment to ongoing research and development positions it as a key player in the field of clinical nutritional products, aimed at enabling caregivers to support patients in achieving optimal health and recovery.
Iolyx Therapeutics
Series A in 2023
Iolyx Therapeutics is a biotechnology company focused on ocular diseases, developing immunology-driven therapies for ophthalmology and advancing a platform for tailored formulations that enable precise local delivery of immunological drugs to ocular tissues, targeting inflammation at its source in both the anterior and posterior segments to improve efficacy, safety, and patient convenience.
Rensair
Series A in 2023
Rensair develops portable hospital-grade air purifiers designed for hospitals, schools and care homes, trusted by businesses worldwide. Its purification technology combines HEPA-grade filtration with ozone-free ultraviolet light to clean the air and reduce airborne contaminants, creating healthier indoor environments while aiming to lower emissions and energy use.
Andromeda Surgical
Seed Round in 2023
Andromeda Surgical develops autonomous robotic systems aimed at enhancing surgical precision, consistency, and efficiency.
Mign
Seed Round in 2023
Mign is a company focused on revolutionizing the design and production of personalized medical devices for musculoskeletal health. It specializes in developing digital solutions for orthopedic products, utilizing proprietary technology that synthesizes complex three-dimensional body data. This approach allows Mign to create custom wearables tailored to individual physical requirements, featuring breathable three-dimensional patterns that enhance comfort and functionality. By integrating advanced design tools and a commitment to sustainability, Mign aims to improve patient outcomes in orthopedic care through innovative and personalized solutions.
Precision Neuroscience
Series B in 2023
Precision Neuroscience is a New York-based neurotechnology company developing a next-generation brain–computer interface platform to enable breakthrough treatments for neurological illnesses affecting billions worldwide. The company aims to deliver minimally invasive, safely removable implants capable of processing large amounts of neural data across multiple brain regions to support therapeutic interventions. Founded in 2021, it focuses on translating neural signals into clinical outcomes, with technology described as a thin-film microelectrode array that conforms to the brain surface without penetrating tissue, enabling broad neural data collection to aid treatment of spinal cord injuries, stroke, and neurodegenerative diseases.
MedCrypt
Series B in 2022
Founded in 2016, MedCrypt specializes in cybersecurity software for medical devices. Its solutions ensure data security and protect against unauthorized access across a wide range of devices, from pacemakers to surgical robots.
Axoft
Seed Round in 2022
Axoft develops implantable, bioinspired electronics that enable long-term communication with the nervous system to improve clinical outcomes and overall health. The company creates ultra-flexible plastic mesh implants housing multiple sensors that closely match brain tissue mechanics, aiming to reduce tissue response and enable precise monitoring and intervention for neurodegenerative conditions. By enhancing brain–machine communication, Axoft seeks to provide more effective treatments for patients with Parkinson's disease and related disorders, supporting tailored therapies and better patient outcomes.
Willow
Series D in 2022
Willow Inc., established in 2014 and headquartered in Mountain View, California, specializes in the manufacture of wearable breast pumps for women. The company offers a range of products including milk bags, accessories such as flanges and tubes, and replacement parts. Willow's flagship product is an in-bra wearable breast pump designed to provide mothers with mobility and hands-free convenience during breastfeeding. The company also provides pumping bras, cases, and other breastfeeding essentials.
Magnetic Insight
Series B in 2022
Magnetic Insight, Inc. is a company specializing in magnetic particle imaging (MPI), an innovative imaging modality that detects iron oxide nanoparticle tracers through time-varying magnetic fields. Founded in 2012 and headquartered in Alameda, California, the company offers several key products, including the MOMENTUM imager, a pre-clinical MPI solution designed to produce high-quality images using advanced magnetic field gradients and proprietary reconstruction processes. Additionally, Magnetic Insight develops VivoTrax, a nanoparticle for cell tracking and as a blood pool agent, and Hyper, an add-on module for the MOMENTUM system that facilitates targeted magnetic hyperthermia treatment. The company's technology enables real-time monitoring of biological events, making significant strides in areas such as quantitative cell tracking, imaging of vascular function, and research into regenerative medicine and CAR-T cell therapies.
Legacy
Series B in 2022
Legacy is a company focused on transforming male fertility through innovative testing and preservation solutions. Founded by healthcare and fertility experts, Legacy provides home-based kits that allow men to analyze, improve, and preserve their sperm without the need to visit a clinic. Their offerings include sperm analysis and cryogenic storage options, facilitating the preservation of fertility for clients in a straightforward and accessible manner. The company collaborates with leading hospitals, fertility clinics, and progressive employers to ensure high-quality services. Legacy has garnered recognition through various awards, including victories at TechCrunch Disrupt and MassChallenge Boston, and has attracted investment from notable firms such as Bain Capital Ventures and Section 32.
Rensair
Series A in 2022
Rensair develops portable hospital-grade air purifiers designed for hospitals, schools and care homes, trusted by businesses worldwide. Its purification technology combines HEPA-grade filtration with ozone-free ultraviolet light to clean the air and reduce airborne contaminants, creating healthier indoor environments while aiming to lower emissions and energy use.
Activ Surgical
Series B in 2022
Activ Surgical is a Boston-based digital surgery company developing a surgical imaging and software platform that uses computer vision, artificial intelligence, analytics, and machine learning to assist surgeons in complex procedures, enhance intraoperative decision-making, improve efficiency and accuracy, and reduce unintended complications. The platform supports augmented reality-based guidance and AI-driven surgery, and its robotic initiatives include the Smart Tissue Autonomous Robot, a system designed to automate aspects of tissue manipulation during surgery.
Cylera
Convertible Note in 2022
Cylera is a healthcare IoT cybersecurity company that protects healthcare organizations from cyber threats and malware by providing a unified, asset-centric platform for managing devices, assessing risks, and detecting threats across the connected IoT environment. Founded in 2017 and based in New York, the company delivers centralized software that identifies all devices, analyzes vulnerabilities, and enables automated threat responses, supporting healthcare providers, enterprises, and government agencies in securing critical medical and operational IoT assets.
Epicore Biosystems
Series A in 2022
Epicore Biosystems, Inc. is a Cambridge, Massachusetts-based company that develops and commercializes a proprietary wearable microfluidic sensing platform designed for athletes. Founded in 2017, the company focuses on analyzing small droplets of sweat directly from the skin to measure a range of health and performance metrics. Its technology allows for non-invasive monitoring of sweat biomarkers, skin health, and physiological states in real-time, facilitating personalized management of hydration, nutrition, and overall health. Epicore's innovative platform is grounded in extensive research in microfluidics and soft materials, aiming to enhance athletic performance and health management through accessible and cost-effective solutions.
Droplette
Series B in 2021
Droplette Inc., founded in 2017 and based in Boston, Massachusetts, specializes in innovative skincare technology through its needle-free device designed for the transdermal delivery of active ingredients. This patent-pending system allows for the administration of drugs significantly larger than those achievable with traditional methods, ensuring deep penetration into the skin over large areas. The painless, contact-free device generates no disposables, offering a portable solution for delivering antibiotics to treat serious skin ulcers and infections, thereby minimizing the risks of secondary complications and antibiotic resistance. Additionally, the company is exploring future applications for localized delivery of chemotherapeutics for skin cancer and anti-aging treatments, aiming to enhance skincare routines while avoiding harmful chemicals.
Kinsa
Series B in 2021
Kinsa, Inc., established in 2012 and headquartered in San Francisco, develops smart thermometers that connect to both Android and iOS devices. These thermometers facilitate communication with individuals who are ill, providing them with care information and enabling data collection to map and track health trends in real-time, thereby aiding in disease spread prevention.
Silvertree
Seed Round in 2021
Silvertree develops stylish, wearable technology designed for active seniors aged 65 and above. Their wrist-worn device prioritizes safety and fosters intergenerational connections, empowering users to maintain independence while providing peace of mind for loved ones.
Looking Glass Factory
Series A in 2021
Founded in 2015, Looking Glass Factory develops and manufactures holographic displays designed for 3D creators. Its flagship product, the Looking Glass, combines light field and volumetric display technologies to enable users to create, share, and interact with 3D content without needing VR or AR headsets.
Leo Cancer Care
Series B in 2021
Leo Cancer Care develops an integrated cancer treatment system designed to simplify radiation therapy and improve patient experience. Founded in Australia, the company promotes upright patient positioning and a shift from machine rotation to patient rotation, supported by global research on its clinical benefits. The system combines three-dimensional imaging with automated control of radiation beams to deliver the appropriate energy to the targeted tissue, enabling radiotherapy centers to reduce pain, time, and cost. It can be integrated with standard radiotherapy equipment to support image-guided delivery and streamlined workflows. By prioritizing patient positioning and precise dose delivery, Leo Cancer Care aims to improve treatment accuracy, accessibility, and safety in cancer care.
Leo Cancer Care
Series B in 2021
Leo Cancer Care develops an integrated cancer treatment system designed to simplify radiation therapy and improve patient experience. Founded in Australia, the company promotes upright patient positioning and a shift from machine rotation to patient rotation, supported by global research on its clinical benefits. The system combines three-dimensional imaging with automated control of radiation beams to deliver the appropriate energy to the targeted tissue, enabling radiotherapy centers to reduce pain, time, and cost. It can be integrated with standard radiotherapy equipment to support image-guided delivery and streamlined workflows. By prioritizing patient positioning and precise dose delivery, Leo Cancer Care aims to improve treatment accuracy, accessibility, and safety in cancer care.
Moons
Series A in 2021
Founded in 2019, Moons specializes in orthodontic solutions, offering transparent dental aligners tailored to each patient's needs. The company provides direct-to-consumer products and online dental services in Mexico and Colombia.
Ascent Integrated Tech
Seed Round in 2021
Ascent develops life-saving technology for first responders, integrating smartwatch data into its Tactical Assault Kit (TAK) platform to enhance firefighter safety, accountability, and operational decision-making. Deployed across major U.S. metro departments and expanding internationally through partnerships.
Willow
Series C in 2021
Willow Inc., established in 2014 and headquartered in Mountain View, California, specializes in the manufacture of wearable breast pumps for women. The company offers a range of products including milk bags, accessories such as flanges and tubes, and replacement parts. Willow's flagship product is an in-bra wearable breast pump designed to provide mothers with mobility and hands-free convenience during breastfeeding. The company also provides pumping bras, cases, and other breastfeeding essentials.
Basil Systems
Seed Round in 2021
Basil Systems offers a SaaS analytics platform that uses machine learning to analyze product, market, and regulatory data for medical device and pharmaceutical companies. The platform provides AI-powered insights to inform product development, market strategy, and clinical decisions, helping clients access essential analytics that guide strategic choices, improve product and supply chain quality, mitigate recall risk, and shorten regulatory approval timelines, enabling the delivery of safe products.
Atentiv Health
Seed Round in 2021
Atentiv Health, established in 2010 and based in Cambridge, Massachusetts, specializes in developing digital learning applications that enhance cognitive function in children and adults. The company's core product, the Atentiv System, is a non-pharmacological, digital cognitive therapy platform that measurably improves attention control. It leverages a non-invasive direct brain-to-computer interface to tailor learning experiences to each user's cognitive signature. Atentiv's offerings include solutions for optimizing attention skills in schoolchildren and applications for rehabilitation of cognitive functions prior to the onset of disorders like Alzheimer's. The company serves education and medical markets in the U.S. and internationally, combining scientific rigor, clinical expertise, and innovative technology to deliver immersive, game-based digital therapeutics.
STIMIT
Venture Round in 2020
STIMIT AG is a medtech company based in Nidau, Switzerland, established in 2018. The company specializes in developing innovative therapies and medical devices aimed at patients who have lost their natural breathing function, particularly those on mechanical ventilation. STIMIT's proprietary technology non-invasively activates the body's own diaphragm, which is often weakened in such patients. By strengthening diaphragm function, the company seeks to facilitate the liberation of patients from ventilators, thereby reducing the time spent on ventilation and improving overall patient outcomes. Additionally, STIMIT is working on second-generation therapies that aim to further enhance the inhalation process for patients. Through these advancements, STIMIT is positioned to significantly impact intensive care practices and improve the quality of life for patients with respiratory challenges.
Shoulder Innovations
Venture Round in 2020
Shoulder Innovations designs and manufactures medical devices for shoulder replacement surgery, focusing on inset glenoid fixation technology to provide a stable glenoid platform and reliable fixation. Its product portfolio includes InSet Total Shoulder Arthroplasty, InSet Reverse Shoulder Arthroplasty, ProVoyance Shoulder Planning Software, and InSet Tray System, along with associated instrumentation. The company distributes its products through partners in the United States and aims to reduce operative time and overall healthcare costs while improving post-surgical implant stability. Founded in 2009, the company is based in Holland, Michigan.
Mission Bio
Venture Round in 2020
Mission Bio develops and delivers tools for studying cellular heterogeneity in human health and life science research. Its flagship product is the Tapestri Platform, a single-cell platform that detects DNA and protein changes, enabling precise detection of heterogeneity in disease progression and treatment response. The company's solutions are primarily applied in oncology, including blood cancers and solid tumors.
Confirm
Venture Round in 2020
Confirm is a reputable and aspirational engineering firm that offers sophisticated automation and validation solutions to manufacturing companies in the pharmaceutical, medical device, and other regulated industries. They guarantee that GMP is used in the most effective way while offering the most value in both technical and commercial terms.
Moons
Seed Round in 2020
Founded in 2019, Moons specializes in orthodontic solutions, offering transparent dental aligners tailored to each patient's needs. The company provides direct-to-consumer products and online dental services in Mexico and Colombia.
Asto CT
Venture Round in 2019
Asto CT is a veterinary imaging company that develops X-ray computed tomography systems for horses, enabling safe, weight-bearing 3D imaging to diagnose and monitor conditions such as lameness, distal limb disease, fractures, and tooth or sinus problems. Its Equina solution provides rapid 3D scans of the lower limbs, head, and neck in standing horses without general anesthesia, supporting early detection and improved treatment planning for Thoroughbreds, other sport and recreation horses, and older animals. The company emphasizes high-quality imaging, ease of use, and integration of advanced robotics with fan-beam CT technology to enhance diagnostic capability and veterinary care. Founded in 2015 and based in Madison, Wisconsin, Asto CT aims to improve horse welfare by enabling safer, more accurate assessment while minimizing anesthesia risks.
Excision BioTherapeutics
Venture Round in 2019
Excision BioTherapeutics Inc. is a life science company based in Philadelphia, Pennsylvania, established in 2015. The company is dedicated to the development and commercialization of gene editing therapeutics aimed at treating life-threatening diseases caused by neurotropic viruses. Utilizing CRISPR-based technology, Excision BioTherapeutics focuses on creating advanced gene-editing medicines that can eradicate or disrupt viral genes in human patients. The company's mission is to advance these therapeutics into safe and effective treatments, significantly improving the lives of individuals affected by viral infections globally.
Emme
Seed Round in 2019
Emme, Inc. is a healthcare technology company based in San Francisco, California, focused on improving women's health, particularly in the area of birth control. The company has developed an integrated smart case device and mobile application designed to help women take their birth control pills consistently. This multi-sensor technology tracks pill consumption, alleviates the need for users to remember to take their medication, and alerts those at risk of unintended pregnancy when back-up contraception is necessary. Additionally, the accompanying app provides users with a comprehensive overview of their health by enabling tracking of menstrual cycles, moods, and side effects. Emme aims to modernize the birth control experience, making it more user-friendly and aligned with the demands of contemporary life.
Notable Labs
Venture Round in 2019
Notable Labs, Inc. is a clinical-stage company that specializes in personalized lab testing services for cancer patients, particularly those with brain cancer. Founded in 2014 and based in Foster City, California, the company utilizes its proprietary Predictive Precision Medicines Platform to conduct drug combination experiments on patients' tumors. This platform allows Notable Labs to simulate cancer treatments and predict patient responses to specific therapies, enabling healthcare providers to prioritize combinations of FDA-approved treatments that can be prescribed without the need for clinical trials. By providing detailed reports to physicians, Notable Labs aims to enhance treatment efficacy and expedite therapeutic development for patients.
Meditrina
Venture Round in 2019
Meditrina, Inc. is a medical device company based in San Jose, California, established in 2016. The company specializes in developing innovative tissue removal solutions specifically designed for intrauterine pathology. Its flagship product, the Aveta System, serves healthcare professionals by providing an all-in-one solution for hysteroscopic diagnostic and therapeutic procedures, such as the removal of polyps and fibroids. The Aveta System is notable for its compact design, which allows for seamless integration into various clinical settings, including offices and operating rooms. It features advanced capabilities such as wide-angle HD hysteroscopy, improved fluid management for better pressure control, and a small insertion diameter coupled with a large working channel, all of which contribute to optimized tissue resection and enhanced procedural efficiency.
Mahmee
Seed Round in 2019
Mahmee is an integrated care delivery platform focused on maternal and infant health. It aims to bridge critical gaps in the U.S. healthcare system, which faces high maternity costs and mortality rates, particularly among Black mothers and infants. By providing a digital infrastructure, Mahmee connects patients, independent health professionals, and large healthcare organizations to enhance access to comprehensive prenatal and postpartum care. The platform features a care management system that links health records for mothers and their babies, identifying clinical risks and facilitating collaboration among maternity and infant care practitioners. This enables healthcare providers to share care plans effectively, ensuring coordinated care. Additionally, Mahmee's marketplace allows new and expecting parents to discover community-based perinatal health providers and access care quickly, both in-person and virtually.
Legacy
Seed Round in 2019
Legacy is a company focused on transforming male fertility through innovative testing and preservation solutions. Founded by healthcare and fertility experts, Legacy provides home-based kits that allow men to analyze, improve, and preserve their sperm without the need to visit a clinic. Their offerings include sperm analysis and cryogenic storage options, facilitating the preservation of fertility for clients in a straightforward and accessible manner. The company collaborates with leading hospitals, fertility clinics, and progressive employers to ensure high-quality services. Legacy has garnered recognition through various awards, including victories at TechCrunch Disrupt and MassChallenge Boston, and has attracted investment from notable firms such as Bain Capital Ventures and Section 32.
Tempo Automation Holdings
Series C in 2019
Tempo Automation Holdings, established in 2013 and headquartered in San Francisco, specializes in manufacturing low-volume electronics products. The company's core business involves designing and assembling printed circuit boards (PCBs) using a unique, software-automated platform. This platform enables Tempo to provide unparalleled speed, quality, and transparency, particularly during the critical prototype and new product introduction stages. Serving leading innovators across industries such as aerospace, medical technology, and automotive, Tempo Automation empowers its customers to accelerate product development and time to market.
Seed Health
Seed Round in 2019
Seed Health is a biotechnology company focused on therapeutics, consumer health innovations, and environmental solutions grounded in microbial sciences. It collaborates with academic researchers to advance discoveries in microbiology and develops health supplements that employ live biotherapeutics, combining probiotics and prebiotics to support digestive health, skin health, heart health, and micronutrient synthesis.
NeuSpera Medical
Series B in 2019
NeuSpera Medical Inc. is a company based in San Jose, California, that specializes in the development and manufacturing of ultra-miniaturized implantable devices designed for neuromodulation therapy. Established in 2013, NeuSpera Medical utilizes its proprietary Mid-Field Powering technology, which harnesses the body as a natural waveguide to transmit energy, allowing for external powering of its implants. This innovative approach facilitates minimally invasive interventions aimed at treating chronic conditions such as Urinary Urgency Incontinence and chronic peripheral nerve pain. The company's focus on bioelectronic medicine positions it as a key player in advancing therapeutic solutions through its cutting-edge implantable technology.
Somna Therapeutics
Venture Round in 2018
Somna Therapeutics LLC, founded in March 2012 in partnership with the Medical College of Wisconsin, is a medical device company based in Germantown, Wisconsin. The company specializes in developing solutions for laryngopharyngeal reflux (LPR) and extraesophageal acid reflux diseases (EERD). Its primary product, the Reza Band, is a non-pharmacologic, investigational device designed to prevent reflux into the larynx, pharynx, and lungs. This non-invasive device aims to improve the quality of life for individuals suffering from these conditions. Somna Therapeutics is currently focused on optimizing product design and completing clinical trials to obtain FDA clearance, with plans to market the Reza Band to hospitals, physician clinics, and home health care providers upon successful approval and launch.
SleepSpace
Venture Round in 2018
SleepSpace is a pioneering company that has developed the first Sleep Operating System aimed at transforming the smart bedroom with integrated technologies. By harnessing the science of sound, vibration, and light, SleepSpace enhances the sleep experience and offers more accurate sleep measurements than traditional wearables. Its proprietary nearable sensing technology allows smartphones to function as smart beds, providing valuable insights for both users and clinicians. The company's platform enables healthcare professionals to deliver personalized sleep programs while gaining comprehensive data on patients' sleep patterns. SleepSpace has established partnerships with major mattress brands, hotels, and corporate wellness initiatives, underscoring its commitment to improving sleep health. Additionally, the company has received substantial funding through grants from the National Institutes of Health, further validating its innovative approach to sleep improvement.
Clear Labs
Series B in 2018
Clear Labs is a biotechnology company specializing in next-generation sequencing and data analytics for infectious disease surveillance and food safety testing. Its platforms, Clear Dx™ and Clear Safety™, enable rapid identification of pathogens, supporting public health initiatives and enhancing safety across various sectors.
Mitra Biotech
Series C in 2018
Mitra Biotech, established in 2010, is a biotechnology company based in Woburn, Massachusetts, with a laboratory office in Bengaluru, India. It specializes in personalized cancer treatment, offering a novel functional assay called CANScript. This assay replicates a patient's tumor microenvironment, measures multiple parameters, and converts them into a single score predicting clinical response to selected therapies. Mitra Biotech's technology aids biopharma companies in drug discovery and development, expanding access to personalized medicine and enhancing cancer treatment selection.
Eva
Venture Round in 2018
Higia Technologies, founded in 2016 and based in Mexico City, specializes in developing EVA, a non-invasive wearable device aimed at assessing breast cancer risk. This innovative device features tactile sensors that map the surface of the breast and its surrounding areas. By continuously monitoring changes in breast temperature, size, and weight through embedded biosensors, EVA empowers women to actively track their breast health. The company's focus is on making breast cancer risk assessment more accessible and user-friendly.
Bainbridge Health
Seed Round in 2018
Bainbridge Health, Inc. is a Philadelphia-based company founded in 2016 that specializes in developing a clinical intelligence and data analytics platform aimed at enhancing medication safety in hospital settings. The company's offerings include a vendor-agnostic medication safety platform that streamlines data management, reducing the reliance on manual data clerking and ad-hoc reporting. Their solutions, designed for medication safety leaders and hospital safety professionals, include an infusion pump management software known as InfusionWare, which centralizes infusion data to improve patient safety and effectively manage pump information. By mitigating medication errors, Bainbridge Health's platform helps healthcare providers reduce avoidable costs and improve overall patient care.
New Aera
Venture Round in 2018
New Aera, Inc., established in 2011 and headquartered in San Ramon, California, is a medical device company specializing in the development, manufacturing, and marketing of products for individuals with acute respiratory conditions. The company's flagship product, SideKick TAV, is a tidal assist ventilator designed to be compatible with various oxygen sources, including concentrators, cylinders, and hospital wall oxygen systems. New Aera's products are aimed at enhancing respiratory therapy, thereby reducing breathlessness and improving the fitness and overall health of cardiac patients.
Emme
Seed Round in 2018
Emme, Inc. is a healthcare technology company based in San Francisco, California, focused on improving women's health, particularly in the area of birth control. The company has developed an integrated smart case device and mobile application designed to help women take their birth control pills consistently. This multi-sensor technology tracks pill consumption, alleviates the need for users to remember to take their medication, and alerts those at risk of unintended pregnancy when back-up contraception is necessary. Additionally, the accompanying app provides users with a comprehensive overview of their health by enabling tracking of menstrual cycles, moods, and side effects. Emme aims to modernize the birth control experience, making it more user-friendly and aligned with the demands of contemporary life.
Innoblative Designs
Venture Round in 2018
Innoblative Designs, Inc. is a medical device company based in Chicago, Illinois, with an additional office in Mansfield, Massachusetts. Established in 2013, the company specializes in the development of innovative electrosurgical devices aimed at enhancing surgical procedures. One of its key products is Sira™, a Saline-assisted Intraoperative Radiofrequency Ablation device. This device utilizes bipolar current to create a controlled zone of ablation during surgery, facilitating the coagulation and ablation of soft tissue beds. Sira's unique design features a saline microinfusion system that ensures optimal contact with target tissue, allowing it to be seamlessly integrated with existing electrosurgical generators in operating rooms. This makes Sira an accessible and effective option for surgeons seeking to improve intraoperative ablation techniques.
Siris Medical
Venture Round in 2018
Founded in 2013, Siris Medical specializes in artificial intelligence-driven treatment decision support systems for radiation therapy in cancer patients. Its flagship product, InsightRT Software Suite, enables efficient management of patient data and offers tools like QuickMatch and PlanMD for personalized treatment recommendations.
NeuSpera Medical
Series B in 2018
NeuSpera Medical Inc. is a company based in San Jose, California, that specializes in the development and manufacturing of ultra-miniaturized implantable devices designed for neuromodulation therapy. Established in 2013, NeuSpera Medical utilizes its proprietary Mid-Field Powering technology, which harnesses the body as a natural waveguide to transmit energy, allowing for external powering of its implants. This innovative approach facilitates minimally invasive interventions aimed at treating chronic conditions such as Urinary Urgency Incontinence and chronic peripheral nerve pain. The company's focus on bioelectronic medicine positions it as a key player in advancing therapeutic solutions through its cutting-edge implantable technology.
ActiveProtective
Series A in 2018
ActiveProtective is a consumer device company that produces smart garments to reduce traumatic injury using wearable airbag technology. The company's proprietary technology uses 3D motion sensors to determine the stereotypical motions and accelerations that govern the body’s normal, daily activities, in order to determine ’departures’ from what is allowable.
This technique called "fall disambiguation", allows users to determine falls prior to impact, intercept hip fractures, and protect themselves from risks during sports and military sessions by deploying micro-airbag protection.
ActiveProtective was founded in 2006 and is based in Allentown, Pennsylvania.
Center Health
Seed Round in 2018
Center Health develops an AI-powered assistant and connected blood sugar meter for managing diabetes. It provides personalized insights through simple logging and collaboration, aiming to help users regain control of their lives.
Horsepower Technologies
Venture Round in 2017
Horsepower Technologies Inc. is an animal healthcare company specializing in the manufacture of rehabilitative orthotics for horses. Founded in 2008 and headquartered in Lowell, Massachusetts, the company develops innovative products designed to facilitate the safe recovery of injured horses. Its flagship product, FastTrack, features protective padding for shock absorption and durability, a hard shell cuff for musculoskeletal support, and a mechanism to limit the extension of the fetlock joint. The technology aids in redirecting weight-bearing forces away from healing tendons and ligaments, allowing horses to resume moderate exercise safely and effectively. Horsepower Technologies sells its products online, aiming to enhance recovery outcomes for horses experiencing lameness.
Respiratory Motion
Venture Round in 2017
Respiratory Motion, Inc. is a medical device company headquartered in Waltham, Massachusetts, that specializes in respiratory monitoring systems. Established in 2011, the company focuses on the development and commercialization of innovative devices designed to monitor respiratory variation and vital respiratory parameters. Its flagship product, ExSpiron, is a point-of-care device that non-invasively measures minute ventilation, tidal volume, and respiratory rate, providing physicians with critical data to enhance patient safety and outcomes. Respiratory Motion's technology enables continuous monitoring across diverse patient populations and clinical environments, offering early warnings of potential respiratory collapse. The company's systems have received FDA clearance, underscoring their commitment to advancing respiratory health care.
Innoblative Designs
Venture Round in 2017
Innoblative Designs, Inc. is a medical device company based in Chicago, Illinois, with an additional office in Mansfield, Massachusetts. Established in 2013, the company specializes in the development of innovative electrosurgical devices aimed at enhancing surgical procedures. One of its key products is Sira™, a Saline-assisted Intraoperative Radiofrequency Ablation device. This device utilizes bipolar current to create a controlled zone of ablation during surgery, facilitating the coagulation and ablation of soft tissue beds. Sira's unique design features a saline microinfusion system that ensures optimal contact with target tissue, allowing it to be seamlessly integrated with existing electrosurgical generators in operating rooms. This makes Sira an accessible and effective option for surgeons seeking to improve intraoperative ablation techniques.
Kinsa
Series B in 2017
Kinsa, Inc., established in 2012 and headquartered in San Francisco, develops smart thermometers that connect to both Android and iOS devices. These thermometers facilitate communication with individuals who are ill, providing them with care information and enabling data collection to map and track health trends in real-time, thereby aiding in disease spread prevention.
Clear Labs
Series B in 2016
Clear Labs is a biotechnology company specializing in next-generation sequencing and data analytics for infectious disease surveillance and food safety testing. Its platforms, Clear Dx™ and Clear Safety™, enable rapid identification of pathogens, supporting public health initiatives and enhancing safety across various sectors.
Pelvalon
Venture Round in 2016
Pelvalon is a medical device company focused on improving the quality of life for women experiencing fecal incontinence. The company develops innovative, non-surgical therapy devices aimed at addressing the challenges associated with pelvic and bowel health. By providing a treatment option that does not involve drugs or hormones, Pelvalon offers a solution for women suffering from accidental bowel leakage, helping them regain bowel control and enhance their overall well-being.
Florence Healthcare
Seed Round in 2016
Florence Healthcare, Inc. is a technology company that specializes in enhancing clinical research through innovative software solutions. Founded in 2014 and based in Atlanta, Georgia, the company develops tools that streamline the management and monitoring of clinical trial data. Its flagship product, the CloudBinder Suite, eliminates redundant data tasks for research sites and facilitates centralized and remote monitoring for sponsors. Additionally, Florence Healthcare offers CloudBinder Redaction software, which allows users to upload documents, redact sensitive patient information with ease, and share these documents with sponsors and contract research organizations. The company primarily serves pharmaceutical, biotechnology, and medical device sponsors, aiming to improve the efficiency and effectiveness of clinical trials.
Spot something off? Help us improve by flagging any incorrect or outdated information. Just email us at support@teaserclub.com. Your feedback is most welcome.